Tiger BioSciences and Advancements in Wound Care
Chronic wounds can severely impact a person's quality of life, leading to negative health outcomes and significantly higher mortality rates, sometimes comparable to certain cancers. Tiger BioSciences has emerged as a leader in this field with its innovative approach to wound care. Their case study focusing on the application of a dehydrated full-thickness placental allograft, named completeFT™, has provided compelling insights into how this technology can change patient experiences.
Understanding Complex Chronic Wounds
Complex, chronic wounds are not just wounds; they are conditions that can lead to severe health issues, including amputations. For instance, patients suffering from diabetic foot ulcers (DFUs) exhibit mortality rates that are alarming, being five times higher than those of patients with breast or prostate cancer. This information emphasizes the necessity for effective treatments that can adapt to a variety of wound types, including venous leg ulcers (VLUs), pressure ulcers, and surgical wounds.
Key Findings from the Study
In a comprehensive study conducted by Tiger BioSciences, 114 patients were treated with weekly applications of completeFT™ in conjunction with standard care methods. This mixture resulted in impressive outcomes, as evidence showed significant reductions in wound size across various categories:
Results of the Clinical Trials
The findings revealed that:
- Out of the analyzed 184 complex wounds, notable progress was observed in several types including DFUs, VLUs, and pressure ulcers.
- By the end of the treatment period, 124 wounds demonstrated a reduction of more than 70%, with many achieving 60% to 100% reduction after only 1-5 applications.
- Statistical analyses further confirmed the treatment's effectiveness, with significant p-values indicating efficacy across all wound types.
As the data reflects, full-thickness placental allografts like completeFT™ have shown potential in decreasing the size of wounds, thereby reducing the necessity for surgical interventions and hospital stays, which ultimately leads to lower healthcare costs.
Implications for Future Treatment
Garrett Grinsfelder, President of Tiger Wound Care, highlighted the transformative nature of the study, stating that this type of allograft can yield meaningful benefits across diverse patient demographics. The simplicity of application makes it suitable not just in traditional settings, but also in mobile care environments. This adaptability could revolutionize care for patients in various situations.
About Tiger BioSciences
Tiger BioSciences is an innovator in the realm of cell and tissue technology, deeply involved in every step of recovery, processing, R&D, and distribution of cellular and acellular products designed for healing. Their commitment to excellence is focused on enhancing the lives of patients, and they are dedicated to providing clinicians with reliable solutions aimed at improving recovery and care.
By working closely with communities and donor families, Tiger BioSciences ensures that their efforts contribute to groundbreaking advancements in medical treatment, making a real difference in the lives of many.
Frequently Asked Questions
What is completeFT™?
CompleteFT™ is a dehydrated, full-thickness placental allograft used in chronic wound care to improve healing outcomes.
How effective is completeFT™ in treating wounds?
The application of completeFT™ has shown to significantly reduce wound sizes, with many patients seeing more than a 70% reduction after treatment.
What types of wounds can benefit from this treatment?
CompleteFT™ has been beneficial for diabetic foot ulcers, venous leg ulcers, pressure sores, and surgical wounds, among others.
Who is Tiger BioSciences?
Tiger BioSciences is a leader in cell and tissue technology dedicated to advancing recovery and care for various medical conditions.
What are the implications of these findings for future wound care?
The research indicates promising potential for broadening the application of placental allografts in diverse care settings, leading to improved patient outcomes and reduced healthcare costs.
